Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 19/20 | 0.54 |
| ▸ | CA2 | P00918 | 19/20 | 0.54 |
| ▸ | CA9 | Q16790 | 14/20 | 0.52 |
| ▸ | CA12 | O43570 | 5/20 | 0.47 |
| ▸ | CA7 | P43166 | 5/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.47 |
| ▸ | CA3 | P07451 | 3/20 | 0.47 |
| ▸ | CA4 | P22748 | 3/20 | 0.47 |
| ▸ | CA6 | P23280 | 3/20 | 0.47 |
| ▸ | CA5A | P35218 | 3/20 | 0.47 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18063393 | 1.00 | CA1 (0.54) | CA1CA2CA9CA12CA7 | |
| SCHEMBL18086664 | 1.00 | CA1 (0.54) | CA1CA2CA9CA12CA7 | |
| SCHEMBL18086670 | 0.81 | CA1 (0.50) | CA1CA2CA9CA12CA7 | |
| SCHEMBL8064670 | 0.80 | USP2 (0.48) | CA1CA2CA9 | |
| SCHEMBL5636350 | 0.80 | USP2 (0.48) | CA1CA2CA9 | |
| SCHEMBL2585295 | 0.79 | CA1 (0.54) | CA1CA2CA9CA12CA7 | |
| SCHEMBL18063462 | 0.78 | LMNA (0.48) | CA1CA2CA9CA12CA7 | |
| SCHEMBL2581605 | 0.77 | CA1 (0.52) | CA1CA2CA9CA12CA7 | |
| SCHEMBL2591059 | 0.77 | CA1 (0.77) | CA1CA2CA9CA12CA7 | |
| SCHEMBL2584427 | 0.76 | CA1 (0.74) | CA1CA2CA9CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104877001-B | Antifungal formulations | 西尼克斯公司 | 2020-07-03 | — | — | CN | disclosed |
| US-9770711-B2 | General catalyst for C-H functionalization | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2017-09-26 | — | — | US | disclosed |
| US-9770711-B2 | General catalyst for C-H functionalization | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2017-09-26 | — | — | US | disclosed |
| US-9770711-B2 | General catalyst for C-H functionalization | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2017-09-26 | — | — | US | disclosed |
| US-20160272662-A1 | GENERAL CATALYST FOR C-H FUNCTIONALIZATION | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2016-09-22 | — | — | US | disclosed |
| US-20160272662-A1 | GENERAL CATALYST FOR C-H FUNCTIONALIZATION | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2016-09-22 | — | — | US | disclosed |
| US-20160272662-A1 | GENERAL CATALYST FOR C-H FUNCTIONALIZATION | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2016-09-22 | — | — | US | disclosed |
| US-8722727-B2 | Antifungal agents | Seynix, Inc. (US) | 2014-05-13 | — | — | US | disclosed |
| US-8722727-B2 | Antifungal agents | Seynix, Inc. (US) | 2014-05-13 | — | — | US | disclosed |
| US-8722727-B2 | Antifungal agents | Seynix, Inc. (US) | 2014-05-13 | — | — | US | disclosed |
| US-20110224228-A1 | ANTIFUNGAL AGENTS | MERCK SHARP & DOHME CORP. (US) | 2011-09-15 | — | — | US | disclosed |
| US-20110224228-A1 | ANTIFUNGAL AGENTS | MERCK SHARP & DOHME CORP. (US) | 2011-09-15 | — | — | US | disclosed |
| EP-2326181-A1 | ANTIFUNGAL AGENTS | Merck Sharp & Dohme Corp. (US) | 2011-06-01 | — | — | EP | disclosed |
| EP-2326180-A1 | ANTIFUNGAL AGENTS | Merck Sharp & Dohme Corp. (US) | 2011-06-01 | — | — | EP | disclosed |
| US-20100113439-A1 | Antifungal agents | MERCK & CO., INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100113439-A1 | Antifungal agents | MERCK & CO., INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100113439-A1 | Antifungal agents | MERCK & CO., INC. (US) | 2010-05-06 | — | — | US | disclosed |
| WO-2010019206-A1 | ANTIFUNGAL AGENTS | MERCK SHARP & DOHME CORP. (US) | 2010-02-18 | — | — | WO | disclosed |
| WO-2010019204-A1 | ANTIFUNGAL AGENTS | MERCK SHARP & DOHME CORP. (US) | 2010-02-18 | — | — | WO | disclosed |
| WO-2010019204-A1 | ANTIFUNGAL AGENTS | MERCK SHARP & DOHME CORP. (US) | 2010-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224228-A1 | ANTIFUNGAL AGENTS | GMDS, GBA3, UGGT1 | CA1 1811/4885CA2 2209/4885CA9 921/4885 |
| US-20160272662-A1 | GENERAL CATALYST FOR C-H FUNCTIONALIZATION | BET1, PLEC, NUDC | CA1 555/4885CA2 1192/4885CA9 517/4885 |
| US-20100113439-A1 | Antifungal agents | GMDS, GBA3, UGGT1 | CA1 2019/4885CA2 2293/4885CA9 1007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.